-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Eterna Therapeutics (NASDAQ:ERNA) Shares Down 7.3%
Eterna Therapeutics (NASDAQ:ERNA) Shares Down 7.3%
Shares of Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) traded down 7.3% during trading on Tuesday . The company traded as low as $3.03 and last traded at $3.18. 13,899 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 54,272 shares. The stock had previously closed at $3.43.
Eterna Therapeutics Stock Performance
The stock has a 50 day moving average of $3.55.
Get Eterna Therapeutics alerts:Insiders Place Their Bets
In related news, Director Nicholas Jason Singer purchased 283,286 shares of the business's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at $873,181.92. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eterna Therapeutics news, major shareholder John D. Halpern acquired 335,920 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was bought at an average price of $3.28 per share, with a total value of $1,101,817.60. Following the purchase, the insider now owns 450,961 shares of the company's stock, valued at $1,479,152.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Jason Singer acquired 283,286 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at approximately $873,181.92. The disclosure for this purchase can be found here. Corporate insiders own 20.50% of the company's stock.
About Eterna Therapeutics
(Get Rating)Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
See Also
- Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) traded down 7.3% during trading on Tuesday . The company traded as low as $3.03 and last traded at $3.18. 13,899 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 54,272 shares. The stock had previously closed at $3.43.
埃特納治療公司(納斯達克代碼:ERNA-GET評級)的股票在週二的交易中下跌了7.3%。該公司股價低至3.03美元,最新報3.18美元。午盤成交量為13,899股,較54,272股的平均成交量下降74%。該股此前收盤價為3.43美元。
Eterna Therapeutics Stock Performance
Eterna Treateutics股票表現
The stock has a 50 day moving average of $3.55.
該股的50日移動均線為3.55美元。
Insiders Place Their Bets
內部人士下注
In related news, Director Nicholas Jason Singer purchased 283,286 shares of the business's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at $873,181.92. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eterna Therapeutics news, major shareholder John D. Halpern acquired 335,920 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was bought at an average price of $3.28 per share, with a total value of $1,101,817.60. Following the purchase, the insider now owns 450,961 shares of the company's stock, valued at $1,479,152.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Jason Singer acquired 283,286 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at approximately $873,181.92. The disclosure for this purchase can be found here. Corporate insiders own 20.50% of the company's stock.
在相關新聞中,董事尼古拉斯·賈森·辛格在12月2日(星期五)的一次交易中購買了283,286股該公司的股票。該股是以每股3.28美元的平均價格收購的,總價值為929,178.08美元。收購完成後,董事現在直接擁有該公司266,214股,價值873,181.92美元。此次收購是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可以通過此超鏈接。在Eterna Treeutics的其他消息中,大股東John D.Halpern在12月2日星期五的交易中收購了該公司股票的335,920股。這只股票是以每股3.28美元的平均價格購買的,總價值為1101,817.60美元。收購完成後,這位內部人士現在擁有450,961股該公司股票,價值1,479,152.08美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可在此超鏈接。此外,在12月2日星期五的一筆交易中,董事尼古拉斯·賈森·辛格購買了283,286股該公司的股票。這只股票是以每股3.28美元的平均成本收購的,總價值為929,178.08美元。收購完成後,董事現在直接擁有該公司266,214股,價值約873,181.92美元。關於這次購買的披露可以找到這裡。公司內部人士持有該公司20.50%的股份。
About Eterna Therapeutics
關於Eterna治療公司
Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
布魯克林免疫療法公司是一家臨床階段的生物製藥公司,致力於開發治療癌症患者的療法。它的先進計劃是IRX-2,這是在頭頸部鱗狀細胞癌患者的2b期臨床試驗中。該公司還開發使用基因編輯和細胞治療技術的療法,用於治療腫瘤學、血液疾病和單基因疾病。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- 免費獲取StockNews.com關於Eterna治療的研究報告(Erna)
- 幫助你建立2023年觀察名單的3只工業股票
- 這些機構選擇CarMax而不是Carvana,你應該這樣做嗎?
- 交易熱圖:如何瞭解隱藏的市場深度
- 美光科技預計2023年底晶片回收
- 新年值得關注的三隻醫療保健便士股
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Eterna治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Eterna Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧